Terlipressin


Generic Medicine Info
Contraindications
Unstable angina, recent MI, septic shock with low cardiac output. Pregnancy.
Special Precautions
Patient with uncontrolled hypertension, severe asthma or COPD, cardiac disease, arrhythmias, atherosclerosis, vascular disease (cerebral or peripheral), electrolyte and fluid disturbances. Renal impairment (especially chronic renal failure). Lactation. Monitoring Parameters Monitor blood pressure, heart rate, serum creatinine, and electrolytes (e.g. Na/K concentrations) daily.
Adverse Reactions
Significant: QT interval prolongation, ventricular arrhythmias (including Torsade de pointes), cutaneous ischaemia and necrosis. Cardiac disorders: Tachycardia, bradycardia, pulmonary oedema, dyspnoea. Gastrointestinal disorders: Intestinal ischaemia, abdominal cramps, diarrhea, nausea, vomiting. Metabolism and nutrition disorders: Rarely, hyponatraemia, hyperglycaemia. Nervous system disorders: Convulsion, headache. Reproductive system and breast disorders: Uterine ischaemia. Respiratory, thoracic and mediastinal disorders: Bronchospasm, respiratory failure. Vascular disorders: Hypertension, hypotension, pallor.
Drug Interactions
Increases the hypotensive effect of non-selective β-blockers. Concomitant use of drugs known to induce bradycardia (e.g. propofol, sufentanil) may lower heart rate and cardiac output. May trigger ventricular arrhythmias, including Torsade de pointes, when used with drugs that can prolong QT interval (e.g. class IA and III antiarrhythmics, erythromycin, certain antihistamines and TCAs), or with drugs that may cause hypokalaemia or hypomagnesaemia.
CIMS Class
Haemostatics
ATC Classification
H01BA04 - terlipressin ; Belongs to the class of vasopressin and analogues. Used in posterior pituitary lobe hormone preparations.
Disclaimer: This information is independently developed by CIMS based on terlipressin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in